<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525029</url>
  </required_header>
  <id_info>
    <org_study_id>2014LS020</org_study_id>
    <nct_id>NCT02525029</nct_id>
  </id_info>
  <brief_title>Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD</brief_title>
  <official_title>Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation (Pregnyl®) to Support Tolerance and Repair As Adjunct Therapy in High-Risk or Refractory Acute Graft-Versus-Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose (MTD) of Pregnyl® when&#xD;
      given in combination with standard immunosuppressive therapy in pediatric and adult patients&#xD;
      with high-risk (Arm 1) or refractory/dependent (Arm 2) aGVHD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: MTD</measure>
    <time_frame>Day 14 after initiation of protocol therapy</time_frame>
    <description>Maximum tolerated dose (MTD) of Pregnyl® when given with standard immunosuppressive therapy in pediatric and adult patients with high-risk or refractory acute graft-versus-host disease (aGVHD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Number of Patients with Complete Response</measure>
    <time_frame>Day 28 after initiation of protocol therapy</time_frame>
    <description>Percentage of complete response among surviving patients at day 28 after initiation of protocol therapy in pediatric and adult patients with high-risk (Arm 1) or refractory (Arm 2) aGVHD. Complete response is defined as a Stage of 0 for all organs with no additional intervening therapy for their GVHD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Number of Patients with Partial Response</measure>
    <time_frame>Day 28 after initiation of protocol therapy</time_frame>
    <description>Percentage of partial response among surviving patients at day 28 after initiation of protocol therapy in pediatric and adult patients with high-risk (Arm 1) or refractory (Arm 2) aGVHD. Partial response is defined as improvement by at least 1 stage in all involved organs without progression in others with no additional intervening therapy for their GVHD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Number of Patients with Mixed Response</measure>
    <time_frame>Day 28 after initiation of protocol therapy</time_frame>
    <description>Percentage of mixed response among surviving patients at day 28 after initiation of protocol therapy in pediatric and adult patients with high-risk (Arm 1) or refractory (Arm 2) aGVHD. Mixed Response is defined as improvement in one organ with deterioration in another organ manifesting symptoms of GVHD or development of symptoms of GVHD in a new organ.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Number of Patients with No Response</measure>
    <time_frame>Day 28 after initiation of protocol therapy</time_frame>
    <description>Percentage of no response among surviving patients at day 28 after initiation of protocol therapy in pediatric and adult patients with high-risk (Arm 1) or refractory (Arm 2) aGVHD. No response is defined as deterioration of any organ involved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Feasibility of hCG Supplementation with Pregnyl®</measure>
    <time_frame>Day 70 after initiation of protocol therapy</time_frame>
    <description>Safety and feasibility of hCG supplementation with Pregnyl® in combination with standard immunosuppressive therapy in pediatric and adult patients with high-risk or refractory aGVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Incidence of aGVHD Flare</measure>
    <time_frame>Day 28 after initiation of protocol therapy</time_frame>
    <description>Incidence of acute GVHD flare after CR/PR requiring increase of steroids or other systemic treatment at days 28 and 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Incidence of aGVHD Flare</measure>
    <time_frame>Day 56 after initiation of protocol therapy</time_frame>
    <description>Incidence of acute GVHD flare after CR/PR requiring increase of steroids or other systemic treatment at days 28 and 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants who fail treatment at Day 28</measure>
    <time_frame>Day 28 after initiation of protocol therapy</time_frame>
    <description>Rate of treatment failure for acute GVHD at days 28 and 56 after initiation of protocol therapy to historical controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of participants who fail treatment at Day 56</measure>
    <time_frame>Day 56 after initiation of protocol therapy</time_frame>
    <description>Rate of treatment failure for acute GVHD at days 28 and 56 after initiation of protocol therapy to historical controls.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Graft vs Host Disease</condition>
  <arm_group>
    <arm_group_label>1: High-Risk aGVHD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses.&#xD;
Individual patient dose reductions: If a patient has toxicity that meets the definition of dose limiting, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.&#xD;
Continue protocol treatment through day 7. Assess response at day 7:&#xD;
If a complete or partial response, continue protocol treatment followed by hCG maintenance twice weekly for 10 doses beginning day 9 to 12.&#xD;
If no response, the patient will be taken off study treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2a: Steroid-Dependent aGVHD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses.&#xD;
Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.&#xD;
Continue protocol treatment through day 14. Assess response at day 14:&#xD;
If a complete or partial response, continue protocol treatment followed by hCG at the assigned dose maintenance twice weekly for 10 doses beginning day 15 to 17.&#xD;
If no response, the patient will be taken off study treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2b: Steroid-Refractory aGVHD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses.&#xD;
Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.&#xD;
Continue protocol treatment through day 14. Assess response at day 14:&#xD;
If a complete or partial response, continue protocol treatment followed by hCG at the assigned dose maintenance twice weekly for 10 doses beginning day 15 to 17.&#xD;
If no response, the patient will be taken off study treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregnyl®</intervention_name>
    <description>ARM 1: High-Risk aGVHD&#xD;
Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for up to 5 doses through day 7:&#xD;
If a complete or partial response, continue protocol treatment followed by hCG maintenance twice weekly for 10 doses beginning day 9 to 12.&#xD;
If no response, the patient will be taken off study treatment&#xD;
Doses for both arms:&#xD;
Phase I: up to 7 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.&#xD;
Phase II: the dose of Pregnyl will be that identified as the MTD during phase I.</description>
    <arm_group_label>1: High-Risk aGVHD</arm_group_label>
    <other_name>Human chorionic gonadotropin (hCG)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregnyl®</intervention_name>
    <description>ARM 2a: Steroid Dependent aGVHD&#xD;
Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for up to 5 doses through day 7:&#xD;
If a complete or partial response, continue protocol treatment followed by hCG maintenance twice weekly for 10 doses beginning day 9 to 12.&#xD;
If no response, the patient will be taken off study treatment&#xD;
Doses for both arms:&#xD;
Phase I: up to 7 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.&#xD;
Phase II: the dose of Pregnyl will be that identified as the MTD during phase I.</description>
    <arm_group_label>2a: Steroid-Dependent aGVHD</arm_group_label>
    <other_name>Human chorionic gonadotropin (hCG)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregnyl®</intervention_name>
    <description>ARM 2b: Steroid-Refractory aGVHD&#xD;
Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for up to 7 doses through day 14:&#xD;
If a complete or partial response, continue protocol treatment followed by hCG at the assigned dose maintenance twice weekly for 10 doses beginning day 15 to 17.&#xD;
If no response, the patient will be taken off study treatment&#xD;
Doses for both arms:&#xD;
Phase I: up to 7 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.&#xD;
Phase II: the dose of Pregnyl will be that identified as the MTD during phase I.</description>
    <arm_group_label>2b: Steroid-Refractory aGVHD</arm_group_label>
    <other_name>Human chorionic gonadotropin (hCG)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute graft versus host disease (GVHD) fitting one of the following categories:&#xD;
&#xD;
               -  High-Risk aGVHD (ARM 1): Pediatric or adult (ages 12-76 years) HCT recipients&#xD;
                  with high-risk acute GVHD, as determined by the refined MN acute GVHD risk score:&#xD;
                  http://z.umn.edu/MNAcuteGVHDRiskScore OR high risk on the basis of blood&#xD;
                  biomarkers (Ann Arbor Score 3 or amphiregulin ≥ 33 pg/ml) or&#xD;
&#xD;
               -  Steroid-Refractory aGVHD (ARM 2): Pediatric or adult (ages 12-76 years) HCT&#xD;
                  recipient with grade II-IV steroid refractory or steroid-dependent acute GVHD,&#xD;
                  defined as any one of the following:&#xD;
&#xD;
                    -  No response of acute GVHD after at least 4 days of systemic corticosteroids&#xD;
                       of at least 2 mg/kg prednisone or equivalent&#xD;
&#xD;
                    -  Progression of acute GVHD within 3 days of systemic corticosteroids of at&#xD;
                       least 2 mg/kg prednisone or equivalent&#xD;
&#xD;
                    -  Failure to improve to at least grade II acute GVHD after 14 days of systemic&#xD;
                       corticosteroids, with initial doses of at least 2 mg/kg prednisone or&#xD;
                       equivalent&#xD;
&#xD;
                    -  Flare of acute GVHD of at least grade II/IV severity despite tapering dose&#xD;
                       of steroids being &gt; 0.5 mg/kg/day.&#xD;
&#xD;
          -  Adequate organ function at study enrollment defined as:&#xD;
&#xD;
               -  Renal: 1.73m2Serum creatinine ≤2.5x upper limit of normal (ULN)&#xD;
&#xD;
               -  Cardiac: Left ventricular ejection fraction (LVEF) ≥ 35%&#xD;
&#xD;
          -  Voluntary written consent (adult or parent/guardian with minor assent for 12 through&#xD;
             17 year olds)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Progressive malignancy&#xD;
&#xD;
          -  Diagnosis of a hormone responsive malignancy&#xD;
&#xD;
          -  Uncontrolled infection at initiation of protocol treatment&#xD;
&#xD;
          -  Current thromboembolic disease requiring full-dose anticoagulation - patients&#xD;
             receiving pharmacologic prophylaxis for thromboembolic disease will be eligible&#xD;
&#xD;
          -  Active or recent (within prior 3 months) thrombus, irrespective of anticoagulation&#xD;
             status&#xD;
&#xD;
          -  Pregnancy as assessed on baseline blood hCG level&#xD;
&#xD;
          -  Unwilling or unable to stop supplemental sex hormone therapy (estrogen, progesterone,&#xD;
             and/or testosterone preparations)&#xD;
&#xD;
          -  Women or men of childbearing potential unwilling to take adequate precautions to avoid&#xD;
             pregnancy from the start of protocol treatment through 28 days after the last&#xD;
             treatment&#xD;
&#xD;
        Screening Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric or adult (ages 0-76 years) HCT recipients&#xD;
&#xD;
          -  Suspected high risk GVHD&#xD;
&#xD;
          -  Voluntary written consent (adult or parent/guardian with minor assent for 12 through&#xD;
             17 year olds)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shernan Holtan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 14, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2015</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GVHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

